These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11074745)

  • 41. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.
    Jacotot B; Benghozi R; Pfister P; Holmes D
    Am J Cardiol; 1995 Jul; 76(2):54A-56A. PubMed ID: 7604799
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.
    Sacks FM; Tonkin AM; Shepherd J; Braunwald E; Cobbe S; Hawkins CM; Keech A; Packard C; Simes J; Byington R; Furberg CD
    Circulation; 2000 Oct; 102(16):1893-900. PubMed ID: 11034935
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction.
    Lacoste L; Lam JY; Hung J; Letchacovski G; Solymoss CB; Waters D
    Circulation; 1995 Dec; 92(11):3172-7. PubMed ID: 7586300
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduction in serum total cholesterol and risks of coronary events and cerebral infarction in Japanese men: the Kyushu Lipid Intervention Study.
    Sasaki J; Arakawa K; Iwashita M; Matsushita Y; Kono S;
    Circ J; 2003 Jun; 67(6):473-8. PubMed ID: 12808261
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study.
    Jones PH; Farmer JA; Cressman MD; McKenney JM; Wright JT; Proctor JD; Berkson DM; Farnham DJ; Wolfson PM; Colfer HT
    Clin Cardiol; 1991 Feb; 14(2):146-51. PubMed ID: 1904333
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ; Davidson MH; Caplan RJ; Pears JS
    Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study). The European Study Group.
    Am J Cardiol; 1992 Nov; 70(15):1281-6. PubMed ID: 1442579
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cholesteryl ester transfer in hypercholesterolaemia: fasting and postprandial studies with and without pravastatin.
    Contacos C; Barter PJ; Vrga L; Sullivan DR
    Atherosclerosis; 1998 Nov; 141(1):87-98. PubMed ID: 9863541
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.
    Pitt B; Mancini GB; Ellis SG; Rosman HS; Park JS; McGovern ME
    J Am Coll Cardiol; 1995 Nov; 26(5):1133-9. PubMed ID: 7594023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. The Simvastatin Pravastatin Study Group.
    Am J Cardiol; 1993 Jun; 71(16):1408-14. PubMed ID: 8517385
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term effects of pravastatin on serum lipid levels in elderly patients with hypercholesterolemia.
    Morimoto S; Koh E; Fukuo K; Higaki J; Ikegami H; Miki T; Hata T; Ogihara T
    Clin Ther; 1994; 16(5):793-803. PubMed ID: 7859238
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project.
    Pfeffer MA; Keech A; Sacks FM; Cobbe SM; Tonkin A; Byington RP; Davis BR; Friedman CP; Braunwald E
    Circulation; 2002 May; 105(20):2341-6. PubMed ID: 12021218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Electrocardiographic events and cholesterol reduction with pravastatin in patients with hypercholesterolemia: the Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial.
    Shimizu M; Koizumi J; Miyamoto S; Origasa H; Mabuchi H;
    Int J Cardiol; 2005 Mar; 99(3):395-401. PubMed ID: 15771919
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia.
    Sebestjen M; Boh M; Keber I
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):999-1003. PubMed ID: 12635468
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [LIPID study [Long-term Intervention with Pravastatin in Ischaemic Disease study]].
    Homma Y
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():416-21. PubMed ID: 11347106
    [No Abstract]   [Full Text] [Related]  

  • 57. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
    Strony J; Hoffman R; Hanson M; Veltri E
    Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced levels of TNF alpha in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks.
    Solheim S; Seljeflot I; Arnesen H; Eritsland J; Eikvar L
    Atherosclerosis; 2001 Aug; 157(2):411-5. PubMed ID: 11472741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. The Quality of Life Multicenter Group.
    Weir MR; Berger ML; Weeks ML; Liss CL; Santanello NC
    Am J Cardiol; 1996 Mar; 77(7):475-9. PubMed ID: 8629587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.